高效抗HIV治疗与甲状腺疾病的相关性探讨
Correlation between highly active anti-HIV therapy and thyroid diseases

徐杰.高效抗HIV治疗与甲状腺疾病的相关性探讨[J].内科急危重症杂志,2017,23(6):492-494

扫码阅读全文

DOI：10.11768/nkjwzzzz20170615

英文关键词:

基金项目:

作者	单位	E-mail
徐杰	延安大学附属医院	baijuan1982@yeah.net

摘要点击次数: 1805

全文下载次数: 2934

中文摘要:

目的:探讨高效抗HIV治疗与甲状腺疾病的相关性。方法:收集2014~2015年之间艾滋病患者111例，分为2组:试验组62例,采用高效抗逆转录病毒疗法(HAART)治疗。对照组49例，未运用HAART治疗。测定2组患者CD4+T淋巴细胞、TSH、FT4、anti-TPO等生化指标，以评估相关性。结果:试验组患者亚临床甲减的患病率显著高于对照组（χ2 =3.965,OR=2.781, 95%CI:0.981~7.884,P=0.046）。其中，试验组患者使用司他夫定后亚临床甲减的患病率（30.00%,6/20）显著高于未使用司他夫定的患者（4.76%,2/42）（χ2=5.420,OR=3.680,95%CI:1.165~11.621,P=0.018）。结论：HAART能显著影响患者的甲状腺疾病患病率，其中司他夫定是亚临床甲减的显著风险因素。

英文摘要:

Objective: To study the correlation between highly active anti-HIV therapy and thyroid diseases. Methods: 111 AIDS patients were collected between 2014-2015, and divided into experimental group (n=62, HAART treatment) and control group (n=49, no HAART treatment), and the data for demographic characteristics and biochemical indicators of CD4+ T lymphocytes, TSH, FT-, anti-TPO, etc. were measured, and the correlation was assessed. Results: The prevalence of subclinical hypothyroidism in experimental group was significantly higher than in control group ( χ2=3.965, OR=2.781, 95% CI: 0.981-7.884, P=0.046). Among them, the prevalence of subclinical hypothyroidism in experimental group using stavudine (20.00%, 6/30) was significantly higher than that in the patients without using stavudine (4.76%, 2/42) (χ2=5.420, OR=3.680, 95% CI:1.165-11.621, P=0.018). Conclusion: HAART could significantly influence the prevalence of thyroid diseases, and stavudine was a significant risk factor for subclinical hypothyroidism.